Endocannabinoid-System-Ecs Medical Cannabis Studies

• View All (505)

Agonistic Properties of Cannabidiol at 5-HT1a Receptors (2005)

This study demonstrates that cannabidiol (CBD) is a modest agonist at the human 5-HT1a receptor. However, additional work and studies are needed to compare the potential of CBD with other serotonin receptors and other species. The results indicate that CBD is potentially useful beyond the domain of cannabinoid receptors. View study
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors (2017)

View study
Anandamide and 2-arachidonoylglycerol- pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids (2012)

There is evidence suggesting that AEA and 2-AG possess specific pharmacological properties and that they also participate in different forms of synaptic plasticity and in different behavioral functions, such as learning and memory, reward and addiction, antinociception and anxiety. View study
Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action (2003)

This research was based on the study of the biphasic effects of cannabinoids on the release of acetylcholine in the hippocampus, site and mechanism of action. The results found in this study could help and provide a theoretical framework for understanding endocannabinoids as modulators of neuronal activity dependent on the state. View study
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors (2006)

This review seeks to verify if cannabidiol is an allosteric modulator in mu and delta opioid receptors. This study showed that cannabidiol is an allosteric modulator in mu and delta opioid receptors. This property is shared by THC but not by rimonabant.10 ?M View study
Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor (2014)

There is convergent anatomical and biochemical evidence that functional CB1 receptors are found in the mitochondria of the brain at low levels. With these data it is possible to conclude that there may be a direct relationship between the CB1 receptor and the mitochondrial functions in the brain and can be detected if certain experimental procedures are applied. View study
Cannabinoid Receptors and Endocannabinoids: Evidence for New Players (2006)

In this research we study the evidence that shows that cannabinoids can modulate synaptic transmission, the cardiovascular system and the immune system through receptors other than CB1 and CB2. View study
Cannabinoid receptors and their ligands (2002)

This research focused on the study of cannabinoid receptors and their ligands. The discovery of the system of cannabinoid and endocannabinoid receptors that form the endocannabinoid system has stimulated the development of selective agonists and antagonists of CB1 and CB2. Reverse agonists. The CB1 / CB2 agonists are already used clinically, as antiemetics or to stimulate the appetite. Possible therapeutic uses of cannabinoid receptor agonists include the treatment of multiple sclerosis / spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, vasodilation that accompanies advanced cirrhosis and cancer. View study
Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain (2011)

Using brain from rats this research focused on the study of the role of CB2 cannabinoid receptors in the brain, we present evidence of the molecular and functional interaction of the CB2 receptor with CB1 cannabinoid receptors. The data obtained in this study show the mechanism by which CB2 receptors can negatively modulate CB1 receptor function. View study
Cannabinoid system and cyclooxygenases inhibitors (2011)

This research focuses its study on summarizing the existing data on the interactions of the nonsteroidal anti-inflammatory drugs NSAIDS-cannabinoids system. It was concluded that some NSAIDs have additional influences on the cannabinoid system either by inhibiting the hydrolase of fatty acid amides (FAAH) or by inhibiting a possible intracellular endocannabinoid transporter. View study
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors (1999)

This investigation was based on the study in rats to verify the mesen- tial vasodilation induced by cannabinoids through an endothelial site different from the CB1 or CB2 receptors. View study
Cannabis and endocannabinoid modulators: Therapeutic promises and challenges (2005)

This summary focuses on cannabis and endocannabinoid modulators and future therapeutic uses and challenges. The article examines the current understanding of CB1, CB2 and other possible cannabinoid receptors View study